Molecular Diagnostics Market Forecast 2025–2035: Global Market to Reach $30.9B
Global Molecular Diagnostics Market Set to Reach $30.9 Billion by 2035: Industry Trends, Technologies, and Key Players Molecular Diagnostics Market Industry Trends and Global Forecasts to 2035: Distribution by Test…
Alpha Cognition Inc. Prices $35 Million Oversubscribed Public Offering of Common Shares
Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares Alpha Cognition Inc. (Nasdaq: ACOG) (the “Company”), a commercial-stage biopharmaceutical company committed to advancing innovative therapies…
LEO Pharma Finalizes Acquisition of Spevigo
LEO Pharma a leading global company in medical dermatology LEO Pharma, a leading global company in medical dermatology, has successfully finalized its acquisition of Spevigo® from Boehringer Ingelheim, as officially…
FIRE1 Norm System Congestion Score Highlighted as Late-Breaking Science at HFSA 2025
FIRE1’s Norm System and Congestion Score Highlighted as Late-Breaking Science at HFSA 2025 FIRE1, a pioneering company in connected medical device solutions, has announced that its innovative heart failure management…
WINREVAIR™ Cuts PAH Clinical Worsening Risk by 76%
Merck Reports Clinical Positive Phase 3 HYPERION Trial Results for WINREVAIR™ (sotatercept-csrk) in Newly Diagnosed Pulmonary Arterial Hypertension Patients Merck known as MSD outside the United States and Canada, today…
Endeavor BioMedicines Shares Positive Phase 2a Taladegib Data
Endeavor BioMedicines Reports Positive Phase 2a Results for Taladegib in Idiopathic Pulmonary Fibrosis, Published in The Lancet Respiratory Medicine Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company focused on developing transformative…
HELIOS-B Phase 3: Vutrisiran Shows Fewer GI Events in ATTR-CM Patients
Alnylam Pharmaceuticals Reports HELIOS-B Phase 3 Findings: Vutrisiran Reduces Gastrointestinal Events in ATTR-CM Patients Alnylam Pharmaceuticals, Inc. , a global leader in RNA interference (RNAi) therapeutics, today unveiled new analyses…
Balchem Showcases Vitamin K2 at FC Bayern Women’s Season Opener
Balchem Kicks Off New Era of Consumer Engagement: Showcasing the Power of Vitamin K2 at FC Bayern Women’s Season Opener When tens of thousands of fans poured into Munich’s Allianz…
International Day of Older Persons: AOP Health Raises Awareness of the Hidden Burden of Venous Leg Ulcers
International Day of Older Persons: AOP Health Brings Urgent Attention to the Silent Burden of Venous Leg Ulcers Every year on October 1, the world observes the United Nations’ International…
ENHERTU Shows Superior Results Over T-DM1 in DESTINY-Breast05 Trial
ENHERTU® Demonstrates Significant Superiority Over T-DM1 in DESTINY-Breast05 Phase 3 Trial for High-Risk HER2 Positive Early Breast Cancer Patients Positive topline results from the planned interim analysis of the DESTINY-Breast05…
Savara Shares Phase 3 IMPALA-2 Trial Results of Molgramostim in aPAP at ERS 2025
Savara Presents New Phase 3 IMPALA-2 Data on Molgramostim for Autoimmune Pulmonary Alveolar Proteinosis at ERS Congress 2025 Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company dedicated to developing therapies…
Quince Therapeutics Publishes eDSP PopPK Modeling Study in CPT: PSP
Quince Therapeutics Publishes Advanced Population PK Modeling Study of eDSP in Pediatric Ataxia-Telangiectasia Patients in CPT: Pharmacometrics & Systems Pharmacology Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company pioneering…